Nemucore Medical Innovations, Inc. is a clinical development company dedicated to the development and commercialization of NMI-900 a life-saving molecularly-targeted therapeutic. NMI-900 is a Best-in-Class Aurora B Kinase inhibitor and this unique mechanism of action could be used to treat newly diagnosed and recurrent cancers.

Nemucore is actively developing NMI-900 and it's companion diagnostic in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).